Articoli correlati a Analyzing T Cell Responses: How to Analyze Cellularimmune...

Analyzing T Cell Responses: How to Analyze Cellularimmune Responses Against Tumor Associated Antigens - Rilegato

 
9781402036224: Analyzing T Cell Responses: How to Analyze Cellularimmune Responses Against Tumor Associated Antigens

Sinossi

Active specific immunotherapy is a promising but investigational modality in the management of cancer patients. Currently, several different cancer vaccine formulations such as peptides, proteins, antigen-pulsed dendritic cells, whole tumor cells, etc. in combination with various adjuvants and carriers are being evaluated in clinical trials (1-3). To determine the optimal cancer vaccine strategy, a surrogate immunological end-point that correlates with clinical outcome needs to be defined, since it would facilitate the rapid comparison of these various formulations. Traditional immunological assays such as ELISA, proliferation and cytotoxicity assays can detect immune responses in vaccinated patients but are not quantitative. In contrast, novel assays such as enzyme-linked immunospot (ELISPOT) assay, intracellular cytokine assay and tetramer assay can quantitate the frequency of antigen-specific T cells. Of these, the ELISPOT assay has the 5 lowest detection limit with 1/10 peripheral blood mononuclear cells (PBMC) and has been determined to be one of the most useful assays to evaluate immune response to cancer vaccines (4). However, the IFN-? ELISPOT assay is not an exclusive measure of cytotoxic T-lymphocyte (CTL) activity as non-cytotoxic cells can also secrete IFN-?. Additionally, CTL with lytic activity do not always secrete IFN-? (5). A more relevant approach to assess functional activity of cytotoxic lymphocytes would be to measure the secretion of molecules that are associated with lytic activity. One of the major mechanisms of cell-mediated cytotoxicity involves exocytosis of cytoplasmic granules from the effector toward the target cell.

Le informazioni nella sezione "Riassunto" possono far riferimento a edizioni diverse di questo titolo.

Recensione

From the reviews of the first edition:

"This book represents the first comprehensive description, and evaluation of the most important assays utilized to monitor immune responses against tumor associated antigens. ... Specifically tailored to the needs of clinical researchers, basic science investigators, and biotechnology innovators, this book provides information that is both sufficiently detailed and eloquently succinct. All discussions are substantiated with a comprehensive literature review. ... Analyzing T Cell Responses provides the most substantial and extensive review of immune response-monitoring techniques available to date." (Melanie Hayden, Stephanie Schroter and Boris Minev, Angiogenesis, Vol. 9, 2006)

Contenuti

Chapter 1: Monitoring Antigen-Specific T Cell Responses; Dirk Nagorsen, Francesco M. Marincola

Chapter 2: Tumor Associated Antigens; Paul F. Robbins

Chapter 3: Immune Escape, Tumor induced immune suppression and immune escape: Mechanisms and Possible Solutions; Theresa L. Whiteside, Michael Campoli, Soldano Ferrone

Chapter 4: Virus Specific T-Cell Responses; Victor Appay

Chapter 5: Cytotoxicity Assays Killer Lymphocytes in Cancer; Gideon Berke & William R. Clark

Chapter 6: Monitoring T Cell Proliferation; Philip D. Hodgkin, Edwin D. Hawkins, Jhaguaral Hasbold, Amanda V. Gett, Elissa K. Deenick, Hilary F. Todd & Mirja Hommel

Chapter 7: Elispot Assay, Assessment of Cellular Immune Responses to Anti-Cancer Vaccines; Theresa L. Whiteside

Chapter 8: Modified Elispot, Modifications of the Elispot Assay for T Cell Monitoring in Cancer Vaccine Trials; Anatoli Malyguine

Chapter 9: Intracellular Cytokine Staining, Cytokine flow cytometry for characterization of tumor-specific T cell responses; Carmen Scheibenbogen, Anne Letsch, Anne Marie Asemissen, Alexander Schmittel, Eckhard Thiel & Ulrich Keilholz

Chapter 10: Cytometric Cytokine Secretion Assay, Detection and Isolation of Antigen-Specific T Cells; Mario Assenmacher

Chapter 11: Peptide/MHC Tetramer Analysis; Peter P. Lee & Francesco M. Marincola

Chapter 12: In Situ MHC Tetramer Staining, In Situ Tetramers; Pamela J. Skinner

Chapter 13: MHC-IG Dimeric Molecules, Dimers - MHC-Ig dimeric molecules for the analysis of antigen-specific T cell responses; Tim F. Greten & Firouzeh Korangy

Chapter 14: TCR Analyses, T-cell receptor CDR3 analysis: Molecular fingerprinting of the T-cell receptor repertoire; Markus J. Maeurer

Chapter 15: Peptide/HLA-GFP Complexes, Detection of Antigen-Specific T Cells by Acquisition of Peptide/Hla-Gfp Complexes; Utano Tomaru, Yoshihisa Yamano & Steven Jacobson

Chapter 16: QRT-PCR, Quantitative RT-PCR for the Analysis of T cell Responses in Immunized Cancer Patients; Udai S. Kammula

Chapter 17: Microarrays, Gene expression profiling approaches for the monitoring of anti-cancer immune responses; Ena Wang

Concluding Remarks; Dirk Nagorsen & Francesco M. Marincola

Le informazioni nella sezione "Su questo libro" possono far riferimento a edizioni diverse di questo titolo.

Compra usato

Condizioni: quasi ottimo
1402036221. Hardcover, from closed...
Visualizza questo articolo

EUR 22,90 per la spedizione da Regno Unito a U.S.A.

Destinazione, tempi e costi

Altre edizioni note dello stesso titolo

9789048169115: Analyzing T Cell Responses: How to analyze cellular immune responses against tumor associated antigens

Edizione in evidenza

ISBN 10:  9048169119 ISBN 13:  9789048169115
Casa editrice: Springer, 2010
Brossura

Risultati della ricerca per Analyzing T Cell Responses: How to Analyze Cellularimmune...

Foto dell'editore

Dirk Nagorsen; F.M. Marincola
Editore: Springer, Netherlands, 2005
ISBN 10: 1402036221 ISBN 13: 9781402036224
Antico o usato Rilegato

Da: The Book Exchange, Macclesfield, CHESH, Regno Unito

Valutazione del venditore 5 su 5 stelle 5 stelle, Maggiori informazioni sulle valutazioni dei venditori

Hardcover. Condizione: Near Fine. 1402036221. Hardcover, from closed pharmaceutical company library. Lending record shows this book has never been borrowed. 313 pages, index, illustrated with charts, tables and diagrams. A critical assessment of all assays that have been used for the monitoring of antigen-specific immune responses. Emphasizes a global approach to the analysis of T cell mediated target/host interactions at the systemic and the peripheral level when such interactions are supposed to occur. Useful in the search of surrogate biomarkers predictive of treatment responsiveness and/or clinical outcome that are of interest to the biotechnology industry. Provides an overview of antigen-specific immune biology in human models of tumor and viral disease, discusses modulation of such responses through immune escape and presents cellular assays (cytoxicity, proliferation, cytokine production using ELISPOT, intracellular staining or cytometric assessment, detection of antigen-specific T cells with tetrameric HLA/epitope complexes or MHC-IG dimers, T cell receptor analysis, assessment of T cell receptor/HLA interactions using peptide/HLA-Green Fluorescent Protein complexes incorporation) and molecular assays including quantitative real-time PCR and gene profiling for evaluation of systemic and peripheral immune responses. Contents clean, tight and bright. Book. Codice articolo 031948

Contatta il venditore

Compra usato

EUR 20,28
Convertire valuta
Spese di spedizione: EUR 22,90
Da: Regno Unito a: U.S.A.
Destinazione, tempi e costi

Quantità: 1 disponibili

Aggiungi al carrello

Foto dell'editore

Editore: Springer, 2005
ISBN 10: 1402036221 ISBN 13: 9781402036224
Nuovo Rilegato

Da: Romtrade Corp., STERLING HEIGHTS, MI, U.S.A.

Valutazione del venditore 5 su 5 stelle 5 stelle, Maggiori informazioni sulle valutazioni dei venditori

Condizione: New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide. Codice articolo ABNR-82553

Contatta il venditore

Compra nuovo

EUR 131,84
Convertire valuta
Spese di spedizione: GRATIS
In U.S.A.
Destinazione, tempi e costi

Quantità: 1 disponibili

Aggiungi al carrello

Foto dell'editore

0
Editore: Springer, 2005
ISBN 10: 1402036221 ISBN 13: 9781402036224
Nuovo Rilegato

Da: Basi6 International, Irving, TX, U.S.A.

Valutazione del venditore 5 su 5 stelle 5 stelle, Maggiori informazioni sulle valutazioni dei venditori

Condizione: Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service. Codice articolo ABEOCT25-153898

Contatta il venditore

Compra nuovo

EUR 131,84
Convertire valuta
Spese di spedizione: GRATIS
In U.S.A.
Destinazione, tempi e costi

Quantità: 1 disponibili

Aggiungi al carrello

Foto dell'editore

Editore: Springer, 2005
ISBN 10: 1402036221 ISBN 13: 9781402036224
Nuovo Rilegato

Da: ALLBOOKS1, Direk, SA, Australia

Valutazione del venditore 5 su 5 stelle 5 stelle, Maggiori informazioni sulle valutazioni dei venditori

Brand new book. Fast ship. Please provide full street address as we are not able to ship to P O box address. Codice articolo SHAK153898

Contatta il venditore

Compra nuovo

EUR 149,02
Convertire valuta
Spese di spedizione: GRATIS
Da: Australia a: U.S.A.
Destinazione, tempi e costi

Quantità: 1 disponibili

Aggiungi al carrello

Foto dell'editore

Editore: Springer, 2005
ISBN 10: 1402036221 ISBN 13: 9781402036224
Nuovo Rilegato

Da: Lucky's Textbooks, Dallas, TX, U.S.A.

Valutazione del venditore 5 su 5 stelle 5 stelle, Maggiori informazioni sulle valutazioni dei venditori

Condizione: New. Codice articolo ABLIING23Mar2411530142909

Contatta il venditore

Compra nuovo

EUR 158,57
Convertire valuta
Spese di spedizione: EUR 3,43
In U.S.A.
Destinazione, tempi e costi

Quantità: Più di 20 disponibili

Aggiungi al carrello

Foto dell'editore

Editore: Springer, 2005
ISBN 10: 1402036221 ISBN 13: 9781402036224
Nuovo Rilegato

Da: Ria Christie Collections, Uxbridge, Regno Unito

Valutazione del venditore 5 su 5 stelle 5 stelle, Maggiori informazioni sulle valutazioni dei venditori

Condizione: New. In. Codice articolo ria9781402036224_new

Contatta il venditore

Compra nuovo

EUR 164,18
Convertire valuta
Spese di spedizione: EUR 13,72
Da: Regno Unito a: U.S.A.
Destinazione, tempi e costi

Quantità: Più di 20 disponibili

Aggiungi al carrello

Immagini fornite dal venditore

Francesco M. Marincola
ISBN 10: 1402036221 ISBN 13: 9781402036224
Nuovo Rilegato
Print on Demand

Da: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Germania

Valutazione del venditore 5 su 5 stelle 5 stelle, Maggiori informazioni sulle valutazioni dei venditori

Buch. Condizione: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Active specific immunotherapy is a promising but investigational modality in the management of cancer patients. Currently, several different cancer vaccine formulations such as peptides, proteins, antigen-pulsed dendritic cells, whole tumor cells, etc. in combination with various adjuvants and carriers are being evaluated in clinical trials (1-3). To determine the optimal cancer vaccine strategy, a surrogate immunological end-point that correlates with clinical outcome needs to be defined, since it would facilitate the rapid comparison of these various formulations. Traditional immunological assays such as ELISA, proliferation and cytotoxicity assays can detect immune responses in vaccinated patients but are not quantitative. In contrast, novel assays such as enzyme-linked immunospot (ELISPOT) assay, intracellular cytokine assay and tetramer assay can quantitate the frequency of antigen-specific T cells. Of these, the ELISPOT assay has the 5 lowest detection limit with 1/10 peripheral blood mononuclear cells (PBMC) and has been determined to be one of the most useful assays to evaluate immune response to cancer vaccines (4). However, the IFN- ELISPOT assay is not an exclusive measure of cytotoxic T-lymphocyte (CTL) activity as non-cytotoxic cells can also secrete IFN- . Additionally, CTL with lytic activity do not always secrete IFN- (5). A more relevant approach to assess functional activity of cytotoxic lymphocytes would be to measure the secretion of molecules that are associated with lytic activity. One of the major mechanisms of cell-mediated cytotoxicity involves exocytosis of cytoplasmic granules from the effector toward the target cell. 328 pp. Englisch. Codice articolo 9781402036224

Contatta il venditore

Compra nuovo

EUR 160,49
Convertire valuta
Spese di spedizione: EUR 23,00
Da: Germania a: U.S.A.
Destinazione, tempi e costi

Quantità: 2 disponibili

Aggiungi al carrello

Immagini fornite dal venditore

Dirk Nagorsen (u. a.)
Editore: Springer, 2005
ISBN 10: 1402036221 ISBN 13: 9781402036224
Nuovo Rilegato
Print on Demand

Da: preigu, Osnabrück, Germania

Valutazione del venditore 5 su 5 stelle 5 stelle, Maggiori informazioni sulle valutazioni dei venditori

Buch. Condizione: Neu. Analyzing T Cell Responses | How to analyze cellular immune responses against tumor associated antigens | Dirk Nagorsen (u. a.) | Buch | xii | Englisch | 2005 | Springer | EAN 9781402036224 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu Print on Demand. Codice articolo 102229227

Contatta il venditore

Compra nuovo

EUR 141,05
Convertire valuta
Spese di spedizione: EUR 70,00
Da: Germania a: U.S.A.
Destinazione, tempi e costi

Quantità: 5 disponibili

Aggiungi al carrello

Immagini fornite dal venditore

Francesco M. Marincola
ISBN 10: 1402036221 ISBN 13: 9781402036224
Nuovo Rilegato

Da: buchversandmimpf2000, Emtmannsberg, BAYE, Germania

Valutazione del venditore 5 su 5 stelle 5 stelle, Maggiori informazioni sulle valutazioni dei venditori

Buch. Condizione: Neu. Neuware -Active specific immunotherapy is a promising but investigational modality in the management of cancer patients. Currently, several different cancer vaccine formulations such as peptides, proteins, antigen-pulsed dendritic cells, whole tumor cells, etc. in combination with various adjuvants and carriers are being evaluated in clinical trials (1-3). To determine the optimal cancer vaccine strategy, a surrogate immunological end-point that correlates with clinical outcome needs to be defined, since it would facilitate the rapid comparison of these various formulations. Traditional immunological assays such as ELISA, proliferation and cytotoxicity assays can detect immune responses in vaccinated patients but are not quantitative. In contrast, novel assays such as enzyme-linked immunospot (ELISPOT) assay, intracellular cytokine assay and tetramer assay can quantitate the frequency of antigen-specific T cells. Of these, the ELISPOT assay has the 5 lowest detection limit with 1/10 peripheral blood mononuclear cells (PBMC) and has been determined to be one of the most useful assays to evaluate immune response to cancer vaccines (4). However, the IFN- ELISPOT assay is not an exclusive measure of cytotoxic T-lymphocyte (CTL) activity as non-cytotoxic cells can also secrete IFN- . Additionally, CTL with lytic activity do not always secrete IFN- (5). A more relevant approach to assess functional activity of cytotoxic lymphocytes would be to measure the secretion of molecules that are associated with lytic activity. One of the major mechanisms of cell-mediated cytotoxicity involves exocytosis of cytoplasmic granules from the effector toward the target cell.Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg 328 pp. Englisch. Codice articolo 9781402036224

Contatta il venditore

Compra nuovo

EUR 160,49
Convertire valuta
Spese di spedizione: EUR 60,00
Da: Germania a: U.S.A.
Destinazione, tempi e costi

Quantità: 2 disponibili

Aggiungi al carrello

Immagini fornite dal venditore

Francesco M. Marincola
ISBN 10: 1402036221 ISBN 13: 9781402036224
Nuovo Rilegato

Da: AHA-BUCH GmbH, Einbeck, Germania

Valutazione del venditore 5 su 5 stelle 5 stelle, Maggiori informazioni sulle valutazioni dei venditori

Buch. Condizione: Neu. Druck auf Anfrage Neuware - Printed after ordering - Active specific immunotherapy is a promising but investigational modality in the management of cancer patients. Currently, several different cancer vaccine formulations such as peptides, proteins, antigen-pulsed dendritic cells, whole tumor cells, etc. in combination with various adjuvants and carriers are being evaluated in clinical trials (1-3). To determine the optimal cancer vaccine strategy, a surrogate immunological end-point that correlates with clinical outcome needs to be defined, since it would facilitate the rapid comparison of these various formulations. Traditional immunological assays such as ELISA, proliferation and cytotoxicity assays can detect immune responses in vaccinated patients but are not quantitative. In contrast, novel assays such as enzyme-linked immunospot (ELISPOT) assay, intracellular cytokine assay and tetramer assay can quantitate the frequency of antigen-specific T cells. Of these, the ELISPOT assay has the 5 lowest detection limit with 1/10 peripheral blood mononuclear cells (PBMC) and has been determined to be one of the most useful assays to evaluate immune response to cancer vaccines (4). However, the IFN- ELISPOT assay is not an exclusive measure of cytotoxic T-lymphocyte (CTL) activity as non-cytotoxic cells can also secrete IFN- . Additionally, CTL with lytic activity do not always secrete IFN- (5). A more relevant approach to assess functional activity of cytotoxic lymphocytes would be to measure the secretion of molecules that are associated with lytic activity. One of the major mechanisms of cell-mediated cytotoxicity involves exocytosis of cytoplasmic granules from the effector toward the target cell. Codice articolo 9781402036224

Contatta il venditore

Compra nuovo

EUR 168,73
Convertire valuta
Spese di spedizione: EUR 63,59
Da: Germania a: U.S.A.
Destinazione, tempi e costi

Quantità: 1 disponibili

Aggiungi al carrello

Vedi altre 2 copie di questo libro

Vedi tutti i risultati per questo libro